Graceway acquires anti-proliferative agent from Gilead
This article was originally published in Scrip
Executive Summary
Graceway Pharmaceuticals, a speciality pharmaceutical firm based in Bristol, Tennessee, has acquired Gilead Sciences' anti-proliferative agent GS 9191, which has completed a Phase II proof of concept study as a topical treatment for genital warts. It did not reveal the financial details of the transaction, which gives it worldwide rights to the product for topical use.